免疫介在性肝炎：Dr Mark Trozzi（マーク・トロッツィ博士）がCOVID-19 mRNAワクチンによる障害報告に関する査読済み論文の約1,000件を掲載したサイトの紹介の続きです。
1000 peer reviewed articles on “Vaccine” injuries
その中で19番目に多くの件数が報告されている「神経症状（Neurological Symptoms）」の論文リストを転載させていただきます。
神経症状： 神経学的副作用および神経学的合併症。医学的には、脳ならびに人体全体に存在する神経および脊髄に影響を及ぼす疾患と定義される。
神経系は非常に多くの身体機能を制御しているため、該当する症状は多岐にわたります。この種の症状には、あらゆる種類の痛みが含まれ、また筋肉の機能、感覚、特殊感覚（視覚、味覚、嗅覚、聴覚）、睡眠、覚醒度（意識）、精神機能（認知）などが影響を受けます。
神経の走行に沿った痛み（坐骨神経痛や 帯状疱疹などでみられる）、筋肉の機能不全（ふるえ、麻痺、不随意運動、歩行障害、筋肉のけいれん・こわばりなど）、しびれ、過敏反応、感覚の消失、めまいなど様々な症状を起こします。
ワクチン接種後の有名な神経症状として，ギラン・バレー症候群，brain fog，頭痛，しびれ，自律神経障害などいろいろあります。
Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence:
https://www.sciencedirect.com/science/article/pii/S0899707121003557
.
Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?:
https://pubmed.ncbi.nlm.nih.gov/34507266/
Spectrum of neurological complications after COVID-19 vaccination:
https://pubmed.ncbi.nlm.nih.gov/34719776/
.
n-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines:
https://pubmed.ncbi.nlm.nih.gov/34688190/
Neurological side effects of SARS-CoV-2 vaccines:
https://pubmed.ncbi.nlm.nih.gov/34750810/
Neurological complications after thefirst dose of COVID-19 vaccines and SARS-CoV-2 infection:
https://pubmed.ncbi.nlm.nih.gov/34697502/
リストには６件しかありませんが、検索すればいくらでも出てきます。
一部の引用だけでもかなりの数になります。
Neurological Complications Following COVID-19 Vaccination
Aparajita Chatterjee
https://link.springer.com/article/10.1007/s11910-022-01247-x
3. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-946. doi: 10.1126/science.abb8923.
4. Forni G, Mantovani A. COVID-19 Commission of Accademia Nazionale dei Lincei, Rome COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626-639. doi: 10.1038/s41418-020-00720-9.
5. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21:83?100. doi: 10.1038/s41577-020-00479-7.
6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603?2615. doi: 10.1056/NEJMoa2034577.
7. ? Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2? preliminary report. N Engl J Med Overseas Ed. 2020;383:1920?31. 10.1056/NEJMoa2022483. This article discusses the mechanism of action and rate of adverse events of the Moderna vaccine against COVID19.
8. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187?201. doi: 10.1056/NEJMoa2101544.
9. ? Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887?97. 10.1016/S0140-6736(20)31866-3. Article discussing the principle of the Sputnik V vaccine along with phase III trial data regarding efficacy and tolerability.
10. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99?111. doi: 10.1016/S0140-6736(20)32661-1.
11. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172?1183. doi: 10.1056/NEJMoa2107659.
12. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173?2184. doi: 10.1016/S0140-6736(21)02000-6.
13. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219?226. doi: 10.1016/j.ijid.2021.08.013.
14. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803?812. doi: 10.1016/S1473-3099(20)30987-7.
15. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427?439. doi: 10.1007/s12291-021-00968-z.
16. Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE-an observational study. Front Public Health. 2022;10:876336. doi: 10.3389/fpubh.2022.876336.
17. Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ. 2022;378:e069445. doi: 10.1136/bmj-2021-069445.
18. Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022;43(1):3?40. doi: 10.1007/s10072-021-05662-9.
19. ?? Garcia-Grimshaw M, Ceballos-Liceaga SE, Hernandez-Vanegas LE, Nunez I, Hernandez-Valdivia N, Carrillo-Garcia DA, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin Immunol. 2021;229:108786. 10.1016/j.clim.2021.108786. The article reports on the incidence of neurological adverse events post-vaccination with the first dose of Pfizer-BioNTech vaccine in a Mexican cohort.
20. Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, et al. Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: a single center experience. J Korean Med Sci. 2021;36(14):e107. doi: 10.3346/jkms.2021.36.e107.
21. Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. 2021;36(21):e153. doi: 10.3346/jkms.2021.36.e153.
